MRUS
Price:
$90
Market Cap:
$6.83B
Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158: In Phase 1 clinical trials for solid tumors. MCLA-145: Also in Phase 1 clinical trials for various so...[Read more]
Industry
Biotechnology
IPO Date
2016-05-19
Stock Exchange
NASDAQ
Ticker
MRUS
According to Merus N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 6.52B. This represents a change of 68.78% compared to the average of 3.86B of the last 4 quarters.
The mean historical Enterprise Value of Merus N.V. over the last ten years is 618.93M. The current 6.52B Enterprise Value has changed 105.28% with respect to the historical average. Over the past ten years (40 quarters), MRUS's Enterprise Value was at its highest in in the September 2025 quarter at 6.82B. The Enterprise Value was at its lowest in in the June 2016 quarter at 8.80M.
Average
618.93M
Median
279.79M
Minimum
82.52M
Maximum
2.42B
Discovering the peaks and valleys of Merus N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 180.16%
Maximum Annual Enterprise Value = 2.42B
Minimum Annual Increase = -59.91%
Minimum Annual Enterprise Value = 82.52M
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | 2.42B | 97.11% |
| 2023 | 1.23B | 118.73% |
| 2022 | 560.62M | -43.43% |
| 2021 | 991.02M | 180.16% |
| 2020 | 353.73M | 162.73% |
| 2019 | 134.64M | 22.03% |
| 2018 | 110.33M | 33.71% |
| 2017 | 82.52M | -59.91% |
| 2016 | 205.84M | 91.96% |
| 2015 | 107.23M | -15.28% |
The current Enterprise Value of Merus N.V. (MRUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.40B
5-year avg
1.11B
10-year avg
618.93M
Merus N.V.’s Enterprise Value is less than Cytokinetics, Incorporated (9.89B), less than Nuvalent, Inc. (8.91B), greater than Abivax S.A. (6.30B), less than Axsome Therapeutics, Inc. (13.04B), less than Metsera, Inc. (6.98B), greater than Rhythm Pharmaceuticals, Inc. (6.23B), less than Jazz Pharmaceuticals plc (18.06B), less than Halozyme Therapeutics, Inc. (10.08B), less than Corcept Therapeutics Incorporated (8.80B), greater than Atrium Therapeutics, Inc. (-53572208.00),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 9.89B | $8.73B | |
| 8.91B | $9.07B | |
| 6.30B | $6.33B | |
| 13.04B | $13.13B | |
| 6.98B | $7.43B | |
| 6.23B | $6.06B | |
| 18.06B | $14.48B | |
| 10.08B | $8.24B | |
| 8.80B | $8.90B | |
| -53572208.00 | $211.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Merus N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Merus N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Merus N.V.'s Enterprise Value?
What is the highest Enterprise Value for Merus N.V. (MRUS)?
What is the 3-year average Enterprise Value for Merus N.V. (MRUS)?
What is the 5-year average Enterprise Value for Merus N.V. (MRUS)?
How does the current Enterprise Value for Merus N.V. (MRUS) compare to its historical average?